Proliferating cell nuclear antigen in prostatic adenocarcinoma: correlation with established prognostic indicators

Area of Science:

• Oncology
• Pathology
• Biomarker Research

Background:

• Prostatic adenocarcinoma prognosis relies on established indicators like tumor grade and stage.
• Proliferating cell nuclear antigen (PCNA) is a nuclear protein associated with cell growth.
• Assessing PCNA expression could offer new prognostic insights for prostate cancer.

Purpose of the Study:

• To evaluate the utility of PCNA as a prognostic variable in prostatic adenocarcinoma.
• To correlate PCNA expression with existing prognostic factors such as tumor grade, stage, PSA, and tumor percentage.
• To determine if PCNA-based proliferative index (PI) can improve prognostic accuracy.

Main Methods:

• Analyzed 40 archival needle biopsies of prostatic adenocarcinoma.
• Utilized immunoperoxidase staining for PCNA (PC10) on paraffin-embedded sections.
• Quantified PCNA expression using image analysis to derive a proliferative index (PI) from at least 425 nuclei per case.

Main Results:

• Proliferative index (PI) values ranged from 2.4% to 31.3%.
• Mean PI values significantly differed across dominant Gleason grades (3, 4, and 5) and Gleason scores (5-7 vs. 8-10).
• No significant linear relationship was found between PI and PSA, clinical stage, or percent tumor at resection.

Conclusions:

• PCNA immunohistochemistry and image analysis show potential as adjunctive prognostic tools for prostate adenocarcinoma.
• The PI may be particularly valuable in assessing needle biopsies where tumor quantity is limited.
• Further research is warranted to fully establish the role of PI in prostate cancer prognostication.